{"filing":{"accession_number":"0001213900-26-110486","cik":"0001596812","ticker":"ENLV","company_name":"Enlivex Ltd.","form":"6-K","filing_date":"2026-10-19","report_date":"2026-10-19","primary_document":"ea0308973-6k_enlivex.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1596812/000121390026110486/ea0308973-6k_enlivex.htm"},"events":[{"id":35972,"run_id":33161,"accession_number":"0001213900-26-110486","anchor_item_number":"EX-99.1","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The press release announces a cost reduction plan effective immediately that includes a workforce reduction of approximately 60%, wind-down of non-clinical R\u0026D activities, and management salary reductions (20% for management, 40% for CEO). This is a material operational restructuring designed to substantially reduce cash burn and refocus resources on the Phase 2b clinical trial. The scale of the workforce reduction and associated operational changes would materially affect a reasonable investor's assessment of the company's financial trajectory and operational capacity.","company_name":"Enlivex Ltd.","ticker":"ENLV","filing_date":"2026-10-19","form":"6-K","submitted_at":null,"items":[{"id":40219,"accession_number":"0001213900-26-110486","item_number":"EX-99.1","item_title":"ea030897301ex99-1.htm","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The press release announces a cost reduction plan effective immediately that includes a workforce reduction of approximately 60%, wind-down of non-clinical R\u0026D activities, and management salary reductions (20% for management, 40% for CEO). This is a material operational restructuring designed to substantially reduce cash burn and refocus resources on the Phase 2b clinical trial. The scale of the workforce reduction and associated operational changes would materially affect a reasonable investor's assessment of the company's financial trajectory and operational capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:19:37.596167+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40219,"accession_number":"0001213900-26-110486","item_number":"EX-99.1","item_title":"ea030897301ex99-1.htm","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The press release announces a cost reduction plan effective immediately that includes a workforce reduction of approximately 60%, wind-down of non-clinical R\u0026D activities, and management salary reductions (20% for management, 40% for CEO). This is a material operational restructuring designed to substantially reduce cash burn and refocus resources on the Phase 2b clinical trial. The scale of the workforce reduction and associated operational changes would materially affect a reasonable investor's assessment of the company's financial trajectory and operational capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:19:37.596167+00:00","company_name":"Enlivex Ltd.","ticker":"ENLV","filing_date":"2026-10-19"}]}